시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 항-CD20 단클론항체 시장 보고서(2025년)
Anti-CD20 Monoclonal Antibodies Global Market Report 2025
상품코드 : 1810825
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

항-CD20 단클론항체 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR)은 7.6%로 120억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 전략적 제휴 및 라이선스 계약의 증가, 병용요법에 대한 광범위한 적용, 재발 또는 난치성 사례의 증가, 신흥국 시장의 의료비 지출 증가 및 접근성 개선, 바이오시밀러의 지속적인 개발 및 승인에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 단클론항체 공학의 혁신, 항-CD20 항체의 병용요법에의 통합, 암 치료의 개별화 기술, 피하 및 장시간 작용하는 제제의 발전, 이중 특이성 및 차세대 항체 개발의 진전 등을 들 수 있습니다.

자가면역질환의 유병률 증가는 항-CD20 단클론항체 시장의 성장을 견인할 것으로 예상됩니다. 자가면역질환은 면역체계가 체내 세포를 잘못 표적으로 삼고 이를 외부의 적으로 간주하여 발생하는 질환입니다. 자가면역질환의 증가는 환경오염물질에 대한 노출 증가와 관련이 있으며, 환경오염물질은 면역 조절을 방해하고 신체 조직에 대한 공격을 유발할 수 있습니다. 항-CD20 단클론항체는 자가 항체를 생성하여 염증을 유발하는 B세포를 표적으로 제거함으로써 자가면역질환 관리에 도움을 줍니다. 이러한 치료법은 면역 활동을 조절하고 질병의 증상을 완화하는 데 도움이 됩니다. 예를 들어, 2024년 6월 정부 기관인 호주 보건 복지 연구소는 2022년 호주에서 약 514,000명(2.0%)이 전신성 자가면역질환인 류마티스 관절염을 앓고 있으며, 여성의 2.5%, 남성의 1.6%가 류마티스 관절염을 앓고 있다고 보고했습니다. 이처럼 자가면역질환의 유병률 증가가 항-CD20 단클론항체 시장의 성장에 기여하고 있습니다.

항-CD20 단클론항체 시장의 주요 기업들은 내성 또는 재발성 B세포 악성종양에 보다 효과적으로 대처하기 위해 오비누투주맙과 같은 새로운 치료제를 개발하고 있습니다. 오비누투주맙은 인간화 II형 항-CD20 단클론항체로서, 특정 혈액암 및 자가면역질환에 관여하는 CD20 양성 B세포를 표적으로 제거합니다. 예를 들어, 2025년 3월 스위스 바이오의약품 회사 로슈는 미국 식품의약국(FDA)이 루푸스 신염 치료제로 가지바/가지바로(오비누츠주맙)의 생물학적 제제 추가 승인 신청(sBLA)을 접수했다고 발표했습니다. 이번 신청은 표준치료제와 병용투여 시 표준치료제 단독요법 대비 완전신장반응(CRR)이 개선되는 것으로 나타난 3상 REGENCY 임상연구의 우수한 결과를 바탕으로 이루어졌습니다. 이로써 가즈바/가즈발로는 루푸스로 인한 심각한 신장 염증인 루푸스 신염 치료에서 이러한 효과를 보인 유일한 항 CD20 단일클론 항체로 자리매김하게 되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Anti-CD20 monoclonal antibodies are targeted immunotherapies designed to bind to the CD20 protein found on the surface of B-cells. These antibodies initiate immune responses such as complement activation and antibody-dependent cell-mediated cytotoxicity, aiding in the destruction of abnormal or malignant B-cells. This focused treatment strategy allows for greater precision and fewer systemic side effects compared to traditional chemotherapy.

The primary types of anti-CD20 monoclonal antibodies include rituximab, obinutuzumab, ofatumumab, and others. Rituximab, which targets CD20, is commonly used in the treatment of B-cell malignancies and autoimmune disorders by depleting abnormal B-cells. It is available in various administration routes, including intravenous and subcutaneous, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online platforms. Rituximab is employed in the treatment of conditions like non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, multiple sclerosis, pemphigus vulgaris, and others. It is utilized by a range of end-users, including hospitals, surgical and diagnostic centers, maternity facilities, ambulatory care units, academic institutions, and other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The anti-CD20 monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides anti-CD20 monoclonal antibodies market statistics, including the anti-CD20 monoclonal antibodies industry global market size, regional shares, competitors with the anti-CD20 monoclonal antibodies market share, detailed anti-CD20 monoclonal antibodies market segments, market trends, opportunities, and any further data you may need to thrive in the anti-CD20 monoclonal antibodies industry. This anti-CD20 monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anti-CD20 monoclonal antibodies market size has grown strongly in recent years. It will grow from $8.33 billion in 2024 to $9.00 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to the increasing prevalence of B-cell malignancies, the expanding use of anti-CD20 therapies in treating autoimmune diseases, a rise in FDA and EMA approvals for new anti-CD20 treatments, and the global increase in the geriatric population.

The anti-CD20 monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.05 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to a rise in strategic collaborations and licensing agreements, broader application in combination therapies, an increasing number of relapsed or refractory cases, higher healthcare spending and improved access in emerging markets, and the continued development and approval of biosimilars. Key trends expected during this period include innovations in monoclonal antibody engineering, the integration of anti-CD20 antibodies into combination treatment regimens, technology-enabled personalization of cancer therapies, advancements in subcutaneous and long-acting formulations, and progress in bispecific and next-generation antibody development.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the anti-CD20 monoclonal antibodies market. Autoimmune diseases arise when the immune system mistakenly targets the body's own cells, treating them as foreign invaders. The increase in autoimmune conditions is linked to greater exposure to environmental pollutants, which can disrupt immune regulation and provoke attacks on the body's tissues. Anti-CD20 monoclonal antibodies help manage autoimmune diseases by targeting and removing B cells responsible for producing autoantibodies and causing inflammation. These therapies aid in regulating immune activity and alleviating disease symptoms. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that in 2022, approximately 514,000 people (2.0%) in Australia were living with rheumatoid arthritis, a systemic autoimmune condition, affecting 2.5% of females and 1.6% of males. Thus, the increasing incidence of autoimmune diseases is contributing to the growth of the anti-CD20 monoclonal antibodies market.

Major players in the anti-CD20 monoclonal antibody market are advancing the development of new therapies such as obinutuzumab to address resistant or relapsed B-cell malignancies more effectively. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that targets and eliminates CD20-positive B cells involved in certain blood cancers and autoimmune disorders. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical firm, announced that the US Food and Drug Administration (FDA) had accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis. This submission is based on positive results from the Phase III REGENCY study, which demonstrated improved complete renal response (CRR) when the drug was combined with standard therapy compared to standard therapy alone. This positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to show such benefits in treating lupus nephritis, a serious kidney inflammation caused by lupus.

In August 2023, TG Therapeutics, a US-based manufacturer of anti-CD20 monoclonal antibodies, formed a partnership with Neuraxpharm to expand the global availability of its multiple sclerosis treatment. The collaboration aims to commercialize BRIUMVI, a CD20-targeted monoclonal antibody therapy, in international markets and increase access for patients with relapsing multiple sclerosis outside the United States. Neuraxpharm is a pharmaceutical company headquartered in Germany.

Major players in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH.

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-CD20 monoclonal antibodies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-CD20 monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-CD20 monoclonal antibodies market consists of sales of tositumomab, ocrelizumab, ublituximab, and mosunetuzumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-CD20 Monoclonal Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-cd20 monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for anti-cd20 monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-cd20 monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Anti-CD20 Monoclonal Antibodies Market Characteristics

3. Anti-CD20 Monoclonal Antibodies Market Trends And Strategies

4. Anti-CD20 Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anti-CD20 Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

6. Anti-CD20 Monoclonal Antibodies Market Segmentation

7. Anti-CD20 Monoclonal Antibodies Market Regional And Country Analysis

8. Asia-Pacific Anti-CD20 Monoclonal Antibodies Market

9. China Anti-CD20 Monoclonal Antibodies Market

10. India Anti-CD20 Monoclonal Antibodies Market

11. Japan Anti-CD20 Monoclonal Antibodies Market

12. Australia Anti-CD20 Monoclonal Antibodies Market

13. Indonesia Anti-CD20 Monoclonal Antibodies Market

14. South Korea Anti-CD20 Monoclonal Antibodies Market

15. Western Europe Anti-CD20 Monoclonal Antibodies Market

16. UK Anti-CD20 Monoclonal Antibodies Market

17. Germany Anti-CD20 Monoclonal Antibodies Market

18. France Anti-CD20 Monoclonal Antibodies Market

19. Italy Anti-CD20 Monoclonal Antibodies Market

20. Spain Anti-CD20 Monoclonal Antibodies Market

21. Eastern Europe Anti-CD20 Monoclonal Antibodies Market

22. Russia Anti-CD20 Monoclonal Antibodies Market

23. North America Anti-CD20 Monoclonal Antibodies Market

24. USA Anti-CD20 Monoclonal Antibodies Market

25. Canada Anti-CD20 Monoclonal Antibodies Market

26. South America Anti-CD20 Monoclonal Antibodies Market

27. Brazil Anti-CD20 Monoclonal Antibodies Market

28. Middle East Anti-CD20 Monoclonal Antibodies Market

29. Africa Anti-CD20 Monoclonal Antibodies Market

30. Anti-CD20 Monoclonal Antibodies Market Competitive Landscape And Company Profiles

31. Anti-CD20 Monoclonal Antibodies Market Other Major And Innovative Companies

32. Global Anti-CD20 Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-CD20 Monoclonal Antibodies Market

34. Recent Developments In The Anti-CD20 Monoclonal Antibodies Market

35. Anti-CD20 Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기